UCLA's Two-Drug Therapy Shows Promise in Reducing Methamphetamine Use
Clinical trial demonstrates significant reduction in methamphetamine use with combination of naltrexone and bupropion over 12 weeks.
- Participants saw a 27% increase in methamphetamine-negative urine tests compared to 11% in the placebo group.
- The ADAPT-2 trial involved over 400 participants across eight sites from 2017 to 2019.
- Methamphetamine use has risen globally, with overdose deaths in the US increasing fivefold from 2012 to 2018.
- Researchers call for further studies to determine the long-term efficacy and optimal treatment duration.
- The study highlights the urgent need for FDA-approved medications to address methamphetamine use disorder.
ScienceDaily 
UPI 